Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
Peter A KaufmanSara A HurvitzJoyce O'ShaughnessyGinny MasonDenise A YardleyAdam M BrufskyHope S RugoMelody CobleighSandra M SwainDebu TripathyAnne MorrisVincent AntaoHaocheng LiMohammad JahanzebPublished in: Breast cancer research and treatment (2021)
Our analysis of real-world data shows that most patients with HER2-positive MBC received first-line treatment with HP + taxane. However, older patients were less likely to receive dual HER2-targeted therapy and chemotherapy.